Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sanofi ("Sanofi" or "the Company") (NASDAQ: SNY). Investors who purchased Sanofi securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Sanofi and certain of its officers and/or directors have violated federal securities laws.
On June 30, 2022, Sanofi announced that “[t]he U.S. Food and Drug Administration (FDA) has placed Phase 3 studies of tolebrutinib in multiple sclerosis (MS) and myasthenia gravis on partial clinical hold. As a result, new enrollment in the United States (U.S.) is paused, and participants in the U.S. who have been in the trial for fewer than 60 days shall suspend study drug.” Sanofi stated that “[t]he FDA action was based on a limited number of cases of drug-induced liver injury that have been identified with tolebrutinib exposure in Phase 3 studies.” On this news, Sanofi’s stock price fell $2.64 per share, or 5.01%, to close at $50.03 per share on June 30, 2022.
If you are aware of any facts relating to this investigation or purchased Sanofi shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.